Showing 901 - 920 results of 3,158 for search 'Patient Number 9', query time: 0.14s Refine Results
  1. 901
  2. 902
  3. 903
  4. 904

    Relationship between the latent profiles of health information-seeking behaviour and glycated haemoglobin levels in patients with type 2 diabetes: a cross-sectional survey in rural... by Xin Zhang, Lin Zeng, Yan-Ping Zhang, Jing-Feng Chen, Chao-Qun Bai, Xiao-Xue Lei, Gui-Fen Fu

    Published 2025-01-01
    “…The glycaemic control rate was defined as the proportion of individuals whose HbA1c levels are less than 7.0%, indicating good control, in relation to the total number of individuals assessed.Results A total of 2178 valid questionnaires were received in this study, and respondents were divided into three categories according to the LPA of their HISB: negative (18.3%), occlusive (46.8%) and inefficient (34.9%). …”
    Get full text
    Article
  5. 905

    RETRACTED ARTICLE: Extracorporeal membrane oxygenation support for SARS-CoV-2: a multi-centered, prospective, observational study in critically ill 92 patients in Saudi Arabia by Saad Alhumaid, Abbas Al Mutair, Header A. Alghazal, Ali J. Alhaddad, Hassan Al-Helal, Sadiq A. Al Salman, Jalal Alali, Sana Almahmoud, Zulfa M. Alhejy, Ahmad A. Albagshi, Javed Muhammad, Amjad Khan, Tarek Sulaiman, Maha Al-Mozaini, Kuldeep Dhama, Jaffar A. Al-Tawfiq, Ali A. Rabaan

    Published 2021-12-01
    “…Also, there was a high number of patients with septic shock (19.6%) and multiple organ failure (10.9%); and more complications occurred at any time during hospitalization [pneumothorax (5% vs 29.3%, p = 0.000), bleeding requiring blood transfusion (7.1% vs 38%, p = 0.000), pulmonary embolism (6.4% vs 15.2%, p = 0.016), and gastrointestinal bleeding (3.3% vs 8.7%, p = 0.017)] in the ECMO group. …”
    Get full text
    Article
  6. 906

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer by Lini Pandite, Simon Metenou, Debra L Richardson, Erika Hamilton, Linda Van Le, Bo Ma, Fatima Rangwala, Nehal J Lakhani, Justin Call, Daphne Stewart, Lauren E Dockery, Guanfang Wang, Jade Huguet, Elliot Offman

    Published 2025-01-01
    “…Treatment-emergent adverse events (TEAEs) were reported for 27 patients (100%), with 24 (88.9%) having a drug-related TEAE and infusion-related reactions being the most common. 12 patients (44.4%) had grade 3/4 TEAEs, and half of these patients (22.2%) had a drug-related grade 3/4 TEAE. …”
    Get full text
    Article
  7. 907
  8. 908
  9. 909
  10. 910
  11. 911
  12. 912
  13. 913
  14. 914

    RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and... by Yao Yang, Yuping Bai, Hongli Yu, Qiang Zhu, Xiaoyu Xie, Yuemin Feng

    Published 2022-06-01
    “…HRs with corresponding 95% CIs were used for meta-analysis.Results 23 studies comprising 2574 patients were included in systematic review. The ORR according to mRECIST is higher than RECIST1.1 (15.9% vs 7.8%, p<0.001). …”
    Get full text
    Article
  15. 915
  16. 916

    High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL by Rudolf A. Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Takahiro Higuchi, Philipp Hartrampf, Sebastian E. Serfling, Thorsten Derlin, Constantin Lapa, Andreas K. Buck, Markus Essler, Kenneth J. Pienta, Mario A. Eisenberger, Mark C. Markowski, Laura Shinehouse, Rehab AbdAllah, Ali Salavati, Martin A. Lodge, Martin G. Pomper, Michael A. Gorin, Ralph A. Bundschuh, Steven P. Rowe

    Published 2022-01-01
    “…On a compartment-based level, wCOVs for volumetric features were ≥22.8%, demonstrating no significant differences between LN and bone lesions (PSMA-TV, P =0.63; TL-PSMA, P =0.9). Findings on an entire tumor burden level were also corroborated in a hottest lesion analysis investigating the SUVmax of the most intense lesion per patient (R2, 0.99; wCOV, 11.2%). …”
    Get full text
    Article
  17. 917
  18. 918
  19. 919
  20. 920